"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_department","contact_institute","contact_address","contact_city","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","age:ch1","ajcc stage:ch1","disease status:ch1","follow-up time (month):ch1","tissue:ch1","vital status:ch1"
"GSM3818017","Breast cancer BRC002","GSM3818017","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Alive","follow-up time (month): 114.1","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC002","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","114.1","Primary breast cancer tumor","Alive"
"GSM3818018","Breast cancer BRC003","GSM3818018","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 1","vital status: Alive","follow-up time (month): 99.133","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC003","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","1","Breast cancer","99.133","Primary breast cancer tumor","Alive"
"GSM3818019","Breast cancer BRC004","GSM3818019","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 25","ajcc stage: 3","vital status: Alive","follow-up time (month): 100.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC004","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","25","3","Breast cancer","100.833","Primary breast cancer tumor","Alive"
"GSM3818020","Breast cancer BRC005","GSM3818020","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 3","vital status: Alive","follow-up time (month): 112.767","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC005","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","3","Breast cancer","112.767","Primary breast cancer tumor","Alive"
"GSM3818021","Breast cancer BRC006","GSM3818021","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 74","ajcc stage: 2","vital status: Dead","follow-up time (month): 28.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC006","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","74","2","Breast cancer","28.333","Primary breast cancer tumor","Dead"
"GSM3818022","Breast cancer BRC007","GSM3818022","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 39","ajcc stage: 2","vital status: Alive","follow-up time (month): 86.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC007","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","39","2","Breast cancer","86.533","Primary breast cancer tumor","Alive"
"GSM3818023","Breast cancer BRC008","GSM3818023","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 3","vital status: Alive","follow-up time (month): 93.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC008","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","3","Breast cancer","93.533","Primary breast cancer tumor","Alive"
"GSM3818024","Breast cancer BRC009","GSM3818024","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 70","ajcc stage: 3","vital status: Alive","follow-up time (month): 45.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC009","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","70","3","Breast cancer","45.9","Primary breast cancer tumor","Alive"
"GSM3818025","Breast cancer BRC011","GSM3818025","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 3","vital status: Dead","follow-up time (month): 23.633","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC011","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","3","Breast cancer","23.633","Primary breast cancer tumor","Dead"
"GSM3818026","Breast cancer BRC012","GSM3818026","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 3","vital status: Alive","follow-up time (month): 111.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC012","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","3","Breast cancer","111.467","Primary breast cancer tumor","Alive"
"GSM3818027","Breast cancer BRC015","GSM3818027","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 2","vital status: Alive","follow-up time (month): 107.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC015","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","2","Breast cancer","107.6","Primary breast cancer tumor","Alive"
"GSM3818028","Breast cancer BRC016E","GSM3818028","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 1","vital status: Alive","follow-up time (month): 115.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC016E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","1","Breast cancer","115.267","Primary breast cancer tumor","Alive"
"GSM3818029","Breast cancer BRC024","GSM3818029","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 36","ajcc stage: 3","vital status: Alive","follow-up time (month): 114.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC024","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","36","3","Breast cancer","114.333","Primary breast cancer tumor","Alive"
"GSM3818030","Breast cancer BRC025","GSM3818030","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 1","vital status: Alive","follow-up time (month): 75.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC025","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","1","Breast cancer","75.3","Primary breast cancer tumor","Alive"
"GSM3818031","Breast cancer BRC026","GSM3818031","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 3","vital status: Alive","follow-up time (month): 105.4","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC026","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","3","Breast cancer","105.4","Primary breast cancer tumor","Alive"
"GSM3818032","Breast cancer BRC027","GSM3818032","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 43","ajcc stage: 1","vital status: Alive","follow-up time (month): 50.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC027","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","43","1","Breast cancer","50.6","Primary breast cancer tumor","Alive"
"GSM3818033","Breast cancer BRC028","GSM3818033","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 56","ajcc stage: 3","vital status: Alive","follow-up time (month): 113.633","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC028","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","56","3","Breast cancer","113.633","Primary breast cancer tumor","Alive"
"GSM3818034","Breast cancer BRC030","GSM3818034","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 49","ajcc stage: 3","vital status: Alive","follow-up time (month): 100.167","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC030","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","49","3","Breast cancer","100.167","Primary breast cancer tumor","Alive"
"GSM3818035","Breast cancer BRC031","GSM3818035","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 58","ajcc stage: 2","vital status: Alive","follow-up time (month): 115.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC031","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","58","2","Breast cancer","115.233","Primary breast cancer tumor","Alive"
"GSM3818036","Breast cancer BRC033","GSM3818036","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Alive","follow-up time (month): 111.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC033","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","111.3","Primary breast cancer tumor","Alive"
"GSM3818037","Breast cancer BRC034","GSM3818037","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 3","vital status: Alive","follow-up time (month): 114.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC034","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","3","Breast cancer","114.067","Primary breast cancer tumor","Alive"
"GSM3818038","Breast cancer BRC035","GSM3818038","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 1","vital status: Alive","follow-up time (month): 110.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC035","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","1","Breast cancer","110.033","Primary breast cancer tumor","Alive"
"GSM3818039","Breast cancer BRC041","GSM3818039","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 3","vital status: Dead","follow-up time (month): 18","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC041","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","3","Breast cancer","18","Primary breast cancer tumor","Dead"
"GSM3818040","Breast cancer BRC043","GSM3818040","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 59","ajcc stage: 1","vital status: Alive","follow-up time (month): 83.367","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC043","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","59","1","Breast cancer","83.367","Primary breast cancer tumor","Alive"
"GSM3818041","Breast cancer BRC045","GSM3818041","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 97.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC045","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","97.867","Primary breast cancer tumor","Alive"
"GSM3818042","Breast cancer BRC046","GSM3818042","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 53","ajcc stage: 2","vital status: Alive","follow-up time (month): 88.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC046","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","53","2","Breast cancer","88.2","Primary breast cancer tumor","Alive"
"GSM3818043","Breast cancer BRC047","GSM3818043","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 60","ajcc stage: 1","vital status: Alive","follow-up time (month): 92.133","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC047","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","60","1","Breast cancer","92.133","Primary breast cancer tumor","Alive"
"GSM3818044","Breast cancer BRC048","GSM3818044","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 1","vital status: Alive","follow-up time (month): 85.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC048","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","1","Breast cancer","85.833","Primary breast cancer tumor","Alive"
"GSM3818045","Breast cancer BRC051","GSM3818045","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 3","vital status: Alive","follow-up time (month): 98.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC051","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","3","Breast cancer","98.467","Primary breast cancer tumor","Alive"
"GSM3818046","Breast cancer BRC052","GSM3818046","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 29","ajcc stage: 2","vital status: Alive","follow-up time (month): 51.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC052","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","29","2","Breast cancer","51.833","Primary breast cancer tumor","Alive"
"GSM3818047","Breast cancer BRC053","GSM3818047","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 71","ajcc stage: 3","vital status: Alive","follow-up time (month): 98","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC053","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","71","3","Breast cancer","98","Primary breast cancer tumor","Alive"
"GSM3818048","Breast cancer BRC054","GSM3818048","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 62","ajcc stage: 1","vital status: Alive","follow-up time (month): 89.4","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC054","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","62","1","Breast cancer","89.4","Primary breast cancer tumor","Alive"
"GSM3818049","Breast cancer BRC055","GSM3818049","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 32","ajcc stage: 1","vital status: Alive","follow-up time (month): 91","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC055","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","32","1","Breast cancer","91","Primary breast cancer tumor","Alive"
"GSM3818050","Breast cancer BRC056","GSM3818050","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 37","ajcc stage: 1","vital status: Alive","follow-up time (month): 50.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC056","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","37","1","Breast cancer","50.8","Primary breast cancer tumor","Alive"
"GSM3818051","Breast cancer BRC059","GSM3818051","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 1","vital status: Alive","follow-up time (month): 83.433","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC059","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","1","Breast cancer","83.433","Primary breast cancer tumor","Alive"
"GSM3818052","Breast cancer BRC061","GSM3818052","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 1","vital status: Alive","follow-up time (month): 46.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC061","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","1","Breast cancer","46.3","Primary breast cancer tumor","Alive"
"GSM3818053","Breast cancer BRC062","GSM3818053","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 57","ajcc stage: 2","vital status: Alive","follow-up time (month): 115.367","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC062","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","57","2","Breast cancer","115.367","Primary breast cancer tumor","Alive"
"GSM3818054","Breast cancer BRC064","GSM3818054","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 56","ajcc stage: 1","vital status: Alive","follow-up time (month): 115.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC064","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","56","1","Breast cancer","115.667","Primary breast cancer tumor","Alive"
"GSM3818055","Breast cancer BRC065","GSM3818055","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 3","vital status: Alive","follow-up time (month): 108.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC065","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","3","Breast cancer","108.033","Primary breast cancer tumor","Alive"
"GSM3818056","Breast cancer BRC066","GSM3818056","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 78","ajcc stage: 2","vital status: Alive","follow-up time (month): 125.167","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC066","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","78","2","Breast cancer","125.167","Primary breast cancer tumor","Alive"
"GSM3818057","Breast cancer BRC069","GSM3818057","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 1","vital status: Alive","follow-up time (month): 116.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC069","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","1","Breast cancer","116.9","Primary breast cancer tumor","Alive"
"GSM3818058","Breast cancer BRC070","GSM3818058","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 2","vital status: Alive","follow-up time (month): 4.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC070","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","2","Breast cancer","4.067","Primary breast cancer tumor","Alive"
"GSM3818059","Breast cancer BRC071","GSM3818059","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 1","vital status: Alive","follow-up time (month): 123.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC071","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","1","Breast cancer","123.9","Primary breast cancer tumor","Alive"
"GSM3818060","Breast cancer BRC072","GSM3818060","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Dead","follow-up time (month): 64.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC072","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","64.067","Primary breast cancer tumor","Dead"
"GSM3818061","Breast cancer BRC073","GSM3818061","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 56","ajcc stage: 3","vital status: Alive","follow-up time (month): 65.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC073","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","56","3","Breast cancer","65.933","Primary breast cancer tumor","Alive"
"GSM3818062","Breast cancer BRC074","GSM3818062","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 52","ajcc stage: 2","vital status: Alive","follow-up time (month): 106.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC074","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","52","2","Breast cancer","106.3","Primary breast cancer tumor","Alive"
"GSM3818063","Breast cancer BRC076","GSM3818063","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 3","vital status: Alive","follow-up time (month): 104.5","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC076","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","3","Breast cancer","104.5","Primary breast cancer tumor","Alive"
"GSM3818064","Breast cancer BRC079","GSM3818064","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 2","vital status: Alive","follow-up time (month): 105","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC079","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","2","Breast cancer","105","Primary breast cancer tumor","Alive"
"GSM3818065","Breast cancer BRC080","GSM3818065","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 112.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC080","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","112.6","Primary breast cancer tumor","Alive"
"GSM3818066","Breast cancer BRC081","GSM3818066","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Alive","follow-up time (month): 122.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC081","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","122.833","Primary breast cancer tumor","Alive"
"GSM3818067","Breast cancer BRC082","GSM3818067","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 28","ajcc stage: 2","vital status: Alive","follow-up time (month): 102.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC082","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","28","2","Breast cancer","102.2","Primary breast cancer tumor","Alive"
"GSM3818068","Breast cancer BRC084","GSM3818068","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 58","ajcc stage: 2","vital status: Alive","follow-up time (month): 146.433","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC084","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","58","2","Breast cancer","146.433","Primary breast cancer tumor","Alive"
"GSM3818069","Breast cancer BRC086","GSM3818069","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 1","vital status: Alive","follow-up time (month): 115.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC086","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","1","Breast cancer","115.033","Primary breast cancer tumor","Alive"
"GSM3818070","Breast cancer BRC089","GSM3818070","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 62","ajcc stage: 1","vital status: Alive","follow-up time (month): 109.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC089","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","62","1","Breast cancer","109.9","Primary breast cancer tumor","Alive"
"GSM3818071","Breast cancer BRC090","GSM3818071","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 36","ajcc stage: 2","vital status: Alive","follow-up time (month): 32","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC090","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","36","2","Breast cancer","32","Primary breast cancer tumor","Alive"
"GSM3818072","Breast cancer BRC091","GSM3818072","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 2","vital status: Alive","follow-up time (month): 24.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC091","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","2","Breast cancer","24.833","Primary breast cancer tumor","Alive"
"GSM3818073","Breast cancer BRC092","GSM3818073","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","vital status: Alive","follow-up time (month): 122.567","","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC092","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44",NA,"Breast cancer","122.567","Primary breast cancer tumor","Alive"
"GSM3818074","Breast cancer BRC095","GSM3818074","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 32","ajcc stage: 3","vital status: Alive","follow-up time (month): 119.967","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC095","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","32","3","Breast cancer","119.967","Primary breast cancer tumor","Alive"
"GSM3818075","Breast cancer BRC096","GSM3818075","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 2","vital status: Alive","follow-up time (month): 113.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC096","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","2","Breast cancer","113.7","Primary breast cancer tumor","Alive"
"GSM3818076","Breast cancer BRC098","GSM3818076","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 104.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC098","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","104.6","Primary breast cancer tumor","Alive"
"GSM3818077","Breast cancer BRC099","GSM3818077","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 3","vital status: Dead","follow-up time (month): 52.633","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC099","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","3","Breast cancer","52.633","Primary breast cancer tumor","Dead"
"GSM3818078","Breast cancer BRC100","GSM3818078","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 1","vital status: Alive","follow-up time (month): 110.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC100","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","1","Breast cancer","110.7","Primary breast cancer tumor","Alive"
"GSM3818079","Breast cancer BRC101","GSM3818079","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 37","ajcc stage: 2","vital status: Alive","follow-up time (month): 111.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC101","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","37","2","Breast cancer","111.6","Primary breast cancer tumor","Alive"
"GSM3818080","Breast cancer BRC102","GSM3818080","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Alive","follow-up time (month): 116.1","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC102","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","116.1","Primary breast cancer tumor","Alive"
"GSM3818081","Breast cancer BRC105","GSM3818081","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 2","vital status: Dead","follow-up time (month): 104.1","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC105","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","2","Breast cancer","104.1","Primary breast cancer tumor","Dead"
"GSM3818082","Breast cancer BRC109","GSM3818082","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 2","vital status: Alive","follow-up time (month): 111.567","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC109","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","2","Breast cancer","111.567","Primary breast cancer tumor","Alive"
"GSM3818083","Breast cancer BRC112","GSM3818083","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 2","vital status: Alive","follow-up time (month): 121.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC112","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","2","Breast cancer","121.867","Primary breast cancer tumor","Alive"
"GSM3818084","Breast cancer BRC113","GSM3818084","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 3","vital status: Alive","follow-up time (month): 125.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC113","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","3","Breast cancer","125.6","Primary breast cancer tumor","Alive"
"GSM3818085","Breast cancer BRC114","GSM3818085","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 3","vital status: Alive","follow-up time (month): 110.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC114","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","3","Breast cancer","110.6","Primary breast cancer tumor","Alive"
"GSM3818086","Breast cancer BRC115","GSM3818086","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 62","ajcc stage: 2","vital status: Alive","follow-up time (month): 126.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC115","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","62","2","Breast cancer","126.3","Primary breast cancer tumor","Alive"
"GSM3818087","Breast cancer BRC117","GSM3818087","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 53","ajcc stage: 2","vital status: Alive","follow-up time (month): 16.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC117","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","53","2","Breast cancer","16.7","Primary breast cancer tumor","Alive"
"GSM3818088","Breast cancer BRC118","GSM3818088","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 65","ajcc stage: 1","vital status: Alive","follow-up time (month): 122.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC118","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","65","1","Breast cancer","122.733","Primary breast cancer tumor","Alive"
"GSM3818089","Breast cancer BRC120","GSM3818089","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 1","vital status: Alive","follow-up time (month): 109.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC120","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","1","Breast cancer","109.667","Primary breast cancer tumor","Alive"
"GSM3818090","Breast cancer BRC121","GSM3818090","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 2","vital status: Alive","follow-up time (month): 112.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC121","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","2","Breast cancer","112.3","Primary breast cancer tumor","Alive"
"GSM3818091","Breast cancer BRC122","GSM3818091","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Alive","follow-up time (month): 112.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC122","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","112.533","Primary breast cancer tumor","Alive"
"GSM3818092","Breast cancer BRC123","GSM3818092","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 2","vital status: Alive","follow-up time (month): 42.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC123","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","2","Breast cancer","42.267","Primary breast cancer tumor","Alive"
"GSM3818093","Breast cancer BRC124","GSM3818093","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 73","ajcc stage: 1","vital status: Dead","follow-up time (month): 101.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC124","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","73","1","Breast cancer","101.233","Primary breast cancer tumor","Dead"
"GSM3818094","Breast cancer BRC125","GSM3818094","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Dead","follow-up time (month): 121.133","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC125","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","121.133","Primary breast cancer tumor","Dead"
"GSM3818095","Breast cancer BRC127","GSM3818095","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 39","ajcc stage: 1","vital status: Alive","follow-up time (month): 102.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC127","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","39","1","Breast cancer","102.8","Primary breast cancer tumor","Alive"
"GSM3818096","Breast cancer BRC129","GSM3818096","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 2","vital status: Alive","follow-up time (month): 105","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC129","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","2","Breast cancer","105","Primary breast cancer tumor","Alive"
"GSM3818097","Breast cancer BRC130","GSM3818097","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 74","ajcc stage: 1","vital status: Dead","follow-up time (month): 115.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC130","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","74","1","Breast cancer","115.467","Primary breast cancer tumor","Dead"
"GSM3818098","Breast cancer BRC132","GSM3818098","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 59","ajcc stage: 2","vital status: Alive","follow-up time (month): 136.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC132","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","59","2","Breast cancer","136.067","Primary breast cancer tumor","Alive"
"GSM3818099","Breast cancer BRC135","GSM3818099","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 60","ajcc stage: 1","vital status: Alive","follow-up time (month): 119.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC135","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","60","1","Breast cancer","119.933","Primary breast cancer tumor","Alive"
"GSM3818100","Breast cancer BRC136","GSM3818100","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Alive","follow-up time (month): 108.4","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC136","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","108.4","Primary breast cancer tumor","Alive"
"GSM3818101","Breast cancer BRC138","GSM3818101","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 2","vital status: Alive","follow-up time (month): 137","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC138","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","2","Breast cancer","137","Primary breast cancer tumor","Alive"
"GSM3818102","Breast cancer BRC140","GSM3818102","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 1","vital status: Alive","follow-up time (month): 131.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC140","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","1","Breast cancer","131.6","Primary breast cancer tumor","Alive"
"GSM3818103","Breast cancer BRC141","GSM3818103","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 3","vital status: Alive","follow-up time (month): 55.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC141","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","3","Breast cancer","55.7","Primary breast cancer tumor","Alive"
"GSM3818104","Breast cancer BRC146","GSM3818104","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 2","vital status: Alive","follow-up time (month): 134.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC146","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","2","Breast cancer","134.467","Primary breast cancer tumor","Alive"
"GSM3818105","Breast cancer BRC149","GSM3818105","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 37","ajcc stage: 2","vital status: Alive","follow-up time (month): 122.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC149","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","37","2","Breast cancer","122.667","Primary breast cancer tumor","Alive"
"GSM3818106","Breast cancer BRC151","GSM3818106","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 51","ajcc stage: 2","vital status: Alive","follow-up time (month): 130","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC151","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","51","2","Breast cancer","130","Primary breast cancer tumor","Alive"
"GSM3818107","Breast cancer BRC152E","GSM3818107","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 49","ajcc stage: 1","vital status: Alive","follow-up time (month): 134.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC152E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","49","1","Breast cancer","134.833","Primary breast cancer tumor","Alive"
"GSM3818108","Breast cancer BRC154","GSM3818108","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Dead","follow-up time (month): 39.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC154","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","39.2","Primary breast cancer tumor","Dead"
"GSM3818109","Breast cancer BRC155","GSM3818109","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 2","vital status: Alive","follow-up time (month): 45.367","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC155","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","2","Breast cancer","45.367","Primary breast cancer tumor","Alive"
"GSM3818110","Breast cancer BRC160","GSM3818110","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 1","vital status: Alive","follow-up time (month): 135.567","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC160","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","1","Breast cancer","135.567","Primary breast cancer tumor","Alive"
"GSM3818111","Breast cancer BRC161","GSM3818111","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 2","vital status: Alive","follow-up time (month): 126.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC161","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","2","Breast cancer","126.233","Primary breast cancer tumor","Alive"
"GSM3818112","Breast cancer BRC167","GSM3818112","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 25","ajcc stage: 2","vital status: Alive","follow-up time (month): 131.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC167","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","25","2","Breast cancer","131.867","Primary breast cancer tumor","Alive"
"GSM3818113","Breast cancer BRC168","GSM3818113","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 3","vital status: Alive","follow-up time (month): 139.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC168","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","3","Breast cancer","139.233","Primary breast cancer tumor","Alive"
"GSM3818114","Breast cancer BRC169","GSM3818114","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 111.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC169","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","111.267","Primary breast cancer tumor","Alive"
"GSM3818115","Breast cancer BRC170","GSM3818115","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 43","ajcc stage: 2","vital status: Alive","follow-up time (month): 125.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC170","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","43","2","Breast cancer","125.8","Primary breast cancer tumor","Alive"
"GSM3818116","Breast cancer BRC171","GSM3818116","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 52","ajcc stage: 3","vital status: Dead","follow-up time (month): 53.133","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC171","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","52","3","Breast cancer","53.133","Primary breast cancer tumor","Dead"
"GSM3818117","Breast cancer BRC174","GSM3818117","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 138.4","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC174","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","138.4","Primary breast cancer tumor","Alive"
"GSM3818118","Breast cancer BRC175","GSM3818118","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 62","ajcc stage: 3","vital status: Dead","follow-up time (month): 5.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC175","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","62","3","Breast cancer","5.233","Primary breast cancer tumor","Dead"
"GSM3818119","Breast cancer BRC176","GSM3818119","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 32","ajcc stage: 1","vital status: Dead","follow-up time (month): 45.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC176","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","32","1","Breast cancer","45.033","Primary breast cancer tumor","Dead"
"GSM3818120","Breast cancer BRC177","GSM3818120","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 56","ajcc stage: 2","vital status: Alive","follow-up time (month): 127.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC177","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","56","2","Breast cancer","127.233","Primary breast cancer tumor","Alive"
"GSM3818121","Breast cancer BRC178","GSM3818121","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 28","ajcc stage: 3","vital status: Alive","follow-up time (month): 134.967","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC178","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","28","3","Breast cancer","134.967","Primary breast cancer tumor","Alive"
"GSM3818122","Breast cancer BRC179","GSM3818122","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 59","ajcc stage: 1","vital status: Alive","follow-up time (month): 142.167","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC179","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","59","1","Breast cancer","142.167","Primary breast cancer tumor","Alive"
"GSM3818123","Breast cancer BRC185","GSM3818123","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 1","vital status: Dead","follow-up time (month): 73.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC185","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","1","Breast cancer","73.733","Primary breast cancer tumor","Dead"
"GSM3818124","Breast cancer BRC186","GSM3818124","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 2","vital status: Alive","follow-up time (month): 38.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC186","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","2","Breast cancer","38.7","Primary breast cancer tumor","Alive"
"GSM3818125","Breast cancer BRC188","GSM3818125","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 39","ajcc stage: 2","vital status: Alive","follow-up time (month): 136.5","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC188","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","39","2","Breast cancer","136.5","Primary breast cancer tumor","Alive"
"GSM3818126","Breast cancer BRC189","GSM3818126","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 58","ajcc stage: 2","vital status: Alive","follow-up time (month): 127.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC189","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","58","2","Breast cancer","127.467","Primary breast cancer tumor","Alive"
"GSM3818127","Breast cancer BRC190","GSM3818127","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 2","vital status: Alive","follow-up time (month): 138.5","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC190","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","2","Breast cancer","138.5","Primary breast cancer tumor","Alive"
"GSM3818128","Breast cancer BRC192","GSM3818128","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 125.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC192","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","125.733","Primary breast cancer tumor","Alive"
"GSM3818129","Breast cancer BRC194","GSM3818129","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 66","ajcc stage: 2","vital status: Alive","follow-up time (month): 100.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC194","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","66","2","Breast cancer","100.3","Primary breast cancer tumor","Alive"
"GSM3818130","Breast cancer BRC195","GSM3818130","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 69","ajcc stage: 2","vital status: Alive","follow-up time (month): 64.567","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC195","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","69","2","Breast cancer","64.567","Primary breast cancer tumor","Alive"
"GSM3818131","Breast cancer BRC197","GSM3818131","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 68","ajcc stage: 1","vital status: Alive","follow-up time (month): 139.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC197","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","68","1","Breast cancer","139.533","Primary breast cancer tumor","Alive"
"GSM3818132","Breast cancer BRC198","GSM3818132","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 99.5","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC198","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","99.5","Primary breast cancer tumor","Alive"
"GSM3818133","Breast cancer BRC199","GSM3818133","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 33","ajcc stage: 2","vital status: Alive","follow-up time (month): 124.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC199","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","33","2","Breast cancer","124.833","Primary breast cancer tumor","Alive"
"GSM3818134","Breast cancer BRC201","GSM3818134","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 55","ajcc stage: 3","vital status: Alive","follow-up time (month): 131.967","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC201","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","55","3","Breast cancer","131.967","Primary breast cancer tumor","Alive"
"GSM3818135","Breast cancer BRC202","GSM3818135","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 51","ajcc stage: 1","vital status: Alive","follow-up time (month): 129.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC202","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","51","1","Breast cancer","129.233","Primary breast cancer tumor","Alive"
"GSM3818136","Breast cancer BRC204","GSM3818136","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 1","vital status: Alive","follow-up time (month): 129.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC204","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","1","Breast cancer","129.667","Primary breast cancer tumor","Alive"
"GSM3818137","Breast cancer BRC205","GSM3818137","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 37","ajcc stage: 2","vital status: Alive","follow-up time (month): 132.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC205","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","37","2","Breast cancer","132.833","Primary breast cancer tumor","Alive"
"GSM3818138","Breast cancer BRC209","GSM3818138","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 130.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC209","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","130.2","Primary breast cancer tumor","Alive"
"GSM3818139","Breast cancer BRC210","GSM3818139","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","vital status: Alive","follow-up time (month): 125.433","","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC210","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54",NA,"Breast cancer","125.433","Primary breast cancer tumor","Alive"
"GSM3818140","Breast cancer BRC211","GSM3818140","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 3","vital status: Alive","follow-up time (month): 28.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC211","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","3","Breast cancer","28.267","Primary breast cancer tumor","Alive"
"GSM3818141","Breast cancer BRC212","GSM3818141","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 3","vital status: Dead","follow-up time (month): 46.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC212","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","3","Breast cancer","46.467","Primary breast cancer tumor","Dead"
"GSM3818142","Breast cancer BRC214","GSM3818142","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 60","vital status: Alive","follow-up time (month): 122.267","","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC214","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","60",NA,"Breast cancer","122.267","Primary breast cancer tumor","Alive"
"GSM3818143","Breast cancer BRC220","GSM3818143","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 3","vital status: Alive","follow-up time (month): 127.767","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC220","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","3","Breast cancer","127.767","Primary breast cancer tumor","Alive"
"GSM3818144","Breast cancer BRC223","GSM3818144","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 2","vital status: Alive","follow-up time (month): 136.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC223","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","2","Breast cancer","136.267","Primary breast cancer tumor","Alive"
"GSM3818145","Breast cancer BRC224","GSM3818145","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 3","vital status: Alive","follow-up time (month): 138.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC224","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","3","Breast cancer","138.2","Primary breast cancer tumor","Alive"
"GSM3818146","Breast cancer BRC225","GSM3818146","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 56","ajcc stage: 2","vital status: Alive","follow-up time (month): 139.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC225","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","56","2","Breast cancer","139.833","Primary breast cancer tumor","Alive"
"GSM3818147","Breast cancer BRC226","GSM3818147","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 1","vital status: Alive","follow-up time (month): 135.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC226","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","1","Breast cancer","135.8","Primary breast cancer tumor","Alive"
"GSM3818148","Breast cancer BRC227","GSM3818148","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Alive","follow-up time (month): 67.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC227","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","67.833","Primary breast cancer tumor","Alive"
"GSM3818149","Breast cancer BRC228","GSM3818149","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 35","ajcc stage: 2","vital status: Dead","follow-up time (month): 91.967","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC228","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","35","2","Breast cancer","91.967","Primary breast cancer tumor","Dead"
"GSM3818150","Breast cancer BRC229","GSM3818150","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 43","ajcc stage: 1","vital status: Alive","follow-up time (month): 4.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC229","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","43","1","Breast cancer","4.733","Primary breast cancer tumor","Alive"
"GSM3818151","Breast cancer BRC230","GSM3818151","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 67","ajcc stage: 2","vital status: Alive","follow-up time (month): 144.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC230","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","67","2","Breast cancer","144.3","Primary breast cancer tumor","Alive"
"GSM3818152","Breast cancer BRC231E","GSM3818152","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 2","vital status: Dead","follow-up time (month): 51.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC231E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","2","Breast cancer","51.9","Primary breast cancer tumor","Dead"
"GSM3818153","Breast cancer BRC232E","GSM3818153","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 60","ajcc stage: 1","vital status: Alive","follow-up time (month): 126","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC232E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","60","1","Breast cancer","126","Primary breast cancer tumor","Alive"
"GSM3818154","Breast cancer BRC233","GSM3818154","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 64","ajcc stage: 1","vital status: Alive","follow-up time (month): 130.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC233","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","64","1","Breast cancer","130.2","Primary breast cancer tumor","Alive"
"GSM3818155","Breast cancer BRC234E","GSM3818155","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 2","vital status: Alive","follow-up time (month): 53.967","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC234E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","2","Breast cancer","53.967","Primary breast cancer tumor","Alive"
"GSM3818156","Breast cancer BRC236","GSM3818156","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 35","ajcc stage: 2","vital status: Dead","follow-up time (month): 47.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC236","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","35","2","Breast cancer","47.7","Primary breast cancer tumor","Dead"
"GSM3818157","Breast cancer BRC237","GSM3818157","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Alive","follow-up time (month): 89.133","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC237","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","89.133","Primary breast cancer tumor","Alive"
"GSM3818158","Breast cancer BRC238","GSM3818158","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 1","vital status: Dead","follow-up time (month): 43.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC238","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","1","Breast cancer","43.267","Primary breast cancer tumor","Dead"
"GSM3818159","Breast cancer BRC239","GSM3818159","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 102.567","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC239","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","102.567","Primary breast cancer tumor","Alive"
"GSM3818160","Breast cancer BRC240E","GSM3818160","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 2","vital status: Alive","follow-up time (month): 150.433","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC240E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","2","Breast cancer","150.433","Primary breast cancer tumor","Alive"
"GSM3818161","Breast cancer BRC241E","GSM3818161","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 57","ajcc stage: 3","vital status: Dead","follow-up time (month): 15.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC241E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","57","3","Breast cancer","15.533","Primary breast cancer tumor","Dead"
"GSM3818162","Breast cancer BRC242","GSM3818162","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 51","ajcc stage: 3","vital status: Alive","follow-up time (month): 133.567","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC242","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","51","3","Breast cancer","133.567","Primary breast cancer tumor","Alive"
"GSM3818163","Breast cancer BRC243E","GSM3818163","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 1","vital status: Alive","follow-up time (month): 149.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC243E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","1","Breast cancer","149.533","Primary breast cancer tumor","Alive"
"GSM3818164","Breast cancer BRC244","GSM3818164","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 39","ajcc stage: 2","vital status: Alive","follow-up time (month): 145.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC244","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","39","2","Breast cancer","145.867","Primary breast cancer tumor","Alive"
"GSM3818165","Breast cancer BRC245","GSM3818165","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 53","ajcc stage: 2","vital status: Alive","follow-up time (month): 146.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC245","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","53","2","Breast cancer","146.067","Primary breast cancer tumor","Alive"
"GSM3818166","Breast cancer BRC246E","GSM3818166","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 3","vital status: Alive","follow-up time (month): 22.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC246E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","3","Breast cancer","22.3","Primary breast cancer tumor","Alive"
"GSM3818167","Breast cancer BRC247","GSM3818167","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 32","ajcc stage: 2","vital status: Alive","follow-up time (month): 74.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC247","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","32","2","Breast cancer","74.2","Primary breast cancer tumor","Alive"
"GSM3818168","Breast cancer BRC249","GSM3818168","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 70","ajcc stage: 3","vital status: Alive","follow-up time (month): 137.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC249","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","70","3","Breast cancer","137.467","Primary breast cancer tumor","Alive"
"GSM3818169","Breast cancer BRC250","GSM3818169","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 43","ajcc stage: 3","vital status: Alive","follow-up time (month): 142.633","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC250","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","43","3","Breast cancer","142.633","Primary breast cancer tumor","Alive"
"GSM3818170","Breast cancer BRC251","GSM3818170","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Alive","follow-up time (month): 147.133","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC251","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","147.133","Primary breast cancer tumor","Alive"
"GSM3818171","Breast cancer BRC253","GSM3818171","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 137","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC253","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","137","Primary breast cancer tumor","Alive"
"GSM3818172","Breast cancer BRC254","GSM3818172","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 49","ajcc stage: 2","vital status: Alive","follow-up time (month): 105.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC254","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","49","2","Breast cancer","105.467","Primary breast cancer tumor","Alive"
"GSM3818173","Breast cancer BRC255","GSM3818173","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 39","ajcc stage: 2","vital status: Alive","follow-up time (month): 131.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC255","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","39","2","Breast cancer","131.733","Primary breast cancer tumor","Alive"
"GSM3818174","Breast cancer BRC257","GSM3818174","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 29","ajcc stage: 3","vital status: Dead","follow-up time (month): 21.767","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC257","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","29","3","Breast cancer","21.767","Primary breast cancer tumor","Dead"
"GSM3818175","Breast cancer BRC259","GSM3818175","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","vital status: Alive","follow-up time (month): 147.533","","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC259","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48",NA,"Breast cancer","147.533","Primary breast cancer tumor","Alive"
"GSM3818176","Breast cancer BRC260E","GSM3818176","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 2","vital status: Alive","follow-up time (month): 129.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC260E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","2","Breast cancer","129.333","Primary breast cancer tumor","Alive"
"GSM3818177","Breast cancer BRC262","GSM3818177","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Alive","follow-up time (month): 131.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC262","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","131.667","Primary breast cancer tumor","Alive"
"GSM3818178","Breast cancer BRC263","GSM3818178","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 2","vital status: Alive","follow-up time (month): 95.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC263","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","2","Breast cancer","95.233","Primary breast cancer tumor","Alive"
"GSM3818179","Breast cancer BRC264","GSM3818179","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 63","ajcc stage: 2","vital status: Alive","follow-up time (month): 131.367","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC264","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","63","2","Breast cancer","131.367","Primary breast cancer tumor","Alive"
"GSM3818180","Breast cancer BRC266","GSM3818180","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 55","ajcc stage: 2","vital status: Alive","follow-up time (month): 30.433","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC266","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","55","2","Breast cancer","30.433","Primary breast cancer tumor","Alive"
"GSM3818181","Breast cancer BRC268","GSM3818181","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 65","ajcc stage: 2","vital status: Dead","follow-up time (month): 66.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC268","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","65","2","Breast cancer","66.933","Primary breast cancer tumor","Dead"
"GSM3818182","Breast cancer BRC269","GSM3818182","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 31","ajcc stage: 2","vital status: Alive","follow-up time (month): 140.967","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC269","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","31","2","Breast cancer","140.967","Primary breast cancer tumor","Alive"
"GSM3818183","Breast cancer BRC270","GSM3818183","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 1","vital status: Alive","follow-up time (month): 140.633","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC270","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","1","Breast cancer","140.633","Primary breast cancer tumor","Alive"
"GSM3818184","Breast cancer BRC271","GSM3818184","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 3","vital status: Alive","follow-up time (month): 151.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC271","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","3","Breast cancer","151.933","Primary breast cancer tumor","Alive"
"GSM3818185","Breast cancer BRC275","GSM3818185","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 53","ajcc stage: 2","vital status: Alive","follow-up time (month): 12.167","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC275","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","53","2","Breast cancer","12.167","Primary breast cancer tumor","Alive"
"GSM3818186","Breast cancer BRC276","GSM3818186","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Alive","follow-up time (month): 139.4","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC276","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","139.4","Primary breast cancer tumor","Alive"
"GSM3818187","Breast cancer BRC278","GSM3818187","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 53","ajcc stage: 2","vital status: Alive","follow-up time (month): 116.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC278","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","53","2","Breast cancer","116.667","Primary breast cancer tumor","Alive"
"GSM3818188","Breast cancer BRC279E","GSM3818188","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Alive","follow-up time (month): 139.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC279E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","139.233","Primary breast cancer tumor","Alive"
"GSM3818189","Breast cancer BRC280","GSM3818189","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 3","vital status: Alive","follow-up time (month): 147.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC280","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","3","Breast cancer","147.033","Primary breast cancer tumor","Alive"
"GSM3818190","Breast cancer BRC281","GSM3818190","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 52","ajcc stage: 2","vital status: Alive","follow-up time (month): 133.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC281","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","52","2","Breast cancer","133.233","Primary breast cancer tumor","Alive"
"GSM3818191","Breast cancer BRC282","GSM3818191","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 36","ajcc stage: 2","vital status: Dead","follow-up time (month): 60.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC282","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","36","2","Breast cancer","60.9","Primary breast cancer tumor","Dead"
"GSM3818192","Breast cancer BRC283","GSM3818192","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 55","ajcc stage: 3","vital status: Alive","follow-up time (month): 133.767","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC283","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","55","3","Breast cancer","133.767","Primary breast cancer tumor","Alive"
"GSM3818193","Breast cancer BRC288","GSM3818193","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 2","vital status: Dead","follow-up time (month): 71.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC288","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","2","Breast cancer","71.6","Primary breast cancer tumor","Dead"
"GSM3818194","Breast cancer BRC289","GSM3818194","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 149.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC289","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","149.733","Primary breast cancer tumor","Alive"
"GSM3818195","Breast cancer BRC291","GSM3818195","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 1","vital status: Alive","follow-up time (month): 146.767","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC291","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","1","Breast cancer","146.767","Primary breast cancer tumor","Alive"
"GSM3818196","Breast cancer BRC292","GSM3818196","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 66","ajcc stage: 2","vital status: Alive","follow-up time (month): 0","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC292","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","66","2","Breast cancer","0","Primary breast cancer tumor","Alive"
"GSM3818197","Breast cancer BRC293","GSM3818197","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 1","vital status: Alive","follow-up time (month): 110.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC293","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","1","Breast cancer","110.833","Primary breast cancer tumor","Alive"
"GSM3818198","Breast cancer BRC294","GSM3818198","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 3","vital status: Alive","follow-up time (month): 44.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC294","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","3","Breast cancer","44.667","Primary breast cancer tumor","Alive"
"GSM3818199","Breast cancer BRC295","GSM3818199","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 61","ajcc stage: 2","vital status: Alive","follow-up time (month): 139.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC295","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","61","2","Breast cancer","139.033","Primary breast cancer tumor","Alive"
"GSM3818200","Breast cancer BRC296","GSM3818200","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 68","ajcc stage: 1","vital status: Alive","follow-up time (month): 149.767","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC296","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","68","1","Breast cancer","149.767","Primary breast cancer tumor","Alive"
"GSM3818201","Breast cancer BRC297E","GSM3818201","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 51","ajcc stage: 2","vital status: Alive","follow-up time (month): 148.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC297E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","51","2","Breast cancer","148.333","Primary breast cancer tumor","Alive"
"GSM3818202","Breast cancer BRC298E","GSM3818202","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 32","ajcc stage: 2","vital status: Alive","follow-up time (month): 141.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC298E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","32","2","Breast cancer","141.267","Primary breast cancer tumor","Alive"
"GSM3818203","Breast cancer BRC300","GSM3818203","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 59","ajcc stage: 2","vital status: Alive","follow-up time (month): 143.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC300","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","59","2","Breast cancer","143.933","Primary breast cancer tumor","Alive"
"GSM3818204","Breast cancer BRC301","GSM3818204","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 2","vital status: Alive","follow-up time (month): 153.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC301","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","2","Breast cancer","153.533","Primary breast cancer tumor","Alive"
"GSM3818205","Breast cancer BRC303","GSM3818205","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 22","ajcc stage: 1","vital status: Dead","follow-up time (month): 129.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC303","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","22","1","Breast cancer","129.333","Primary breast cancer tumor","Dead"
"GSM3818206","Breast cancer BRC304","GSM3818206","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 29","ajcc stage: 2","vital status: Alive","follow-up time (month): 146.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC304","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","29","2","Breast cancer","146.067","Primary breast cancer tumor","Alive"
"GSM3818207","Breast cancer BRC305","GSM3818207","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Alive","follow-up time (month): 48.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC305","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","48.7","Primary breast cancer tumor","Alive"
"GSM3818208","Breast cancer BRC306","GSM3818208","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 32","ajcc stage: 2","vital status: Dead","follow-up time (month): 131.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC306","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","32","2","Breast cancer","131.867","Primary breast cancer tumor","Dead"
"GSM3818209","Breast cancer BRC307","GSM3818209","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 57.4","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC307","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","57.4","Primary breast cancer tumor","Alive"
"GSM3818210","Breast cancer BRC308","GSM3818210","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 43","ajcc stage: 1","vital status: Alive","follow-up time (month): 56.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC308","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","43","1","Breast cancer","56.867","Primary breast cancer tumor","Alive"
"GSM3818211","Breast cancer BRC309","GSM3818211","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 36","ajcc stage: 3","vital status: Dead","follow-up time (month): 119.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC309","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","36","3","Breast cancer","119.033","Primary breast cancer tumor","Dead"
"GSM3818212","Breast cancer BRC312","GSM3818212","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 31","ajcc stage: 2","vital status: Alive","follow-up time (month): 155.167","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC312","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","31","2","Breast cancer","155.167","Primary breast cancer tumor","Alive"
"GSM3818213","Breast cancer BRC313E","GSM3818213","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 53","ajcc stage: 3","vital status: Alive","follow-up time (month): 62.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC313E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","53","3","Breast cancer","62.533","Primary breast cancer tumor","Alive"
"GSM3818214","Breast cancer BRC318","GSM3818214","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 53","ajcc stage: 1","vital status: Dead","follow-up time (month): 17.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC318","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","53","1","Breast cancer","17.267","Primary breast cancer tumor","Dead"
"GSM3818215","Breast cancer BRC319E","GSM3818215","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 3","vital status: Alive","follow-up time (month): 133.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC319E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","3","Breast cancer","133.7","Primary breast cancer tumor","Alive"
"GSM3818216","Breast cancer BRC321","GSM3818216","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 3","vital status: Alive","follow-up time (month): 147.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC321","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","3","Breast cancer","147.733","Primary breast cancer tumor","Alive"
"GSM3818217","Breast cancer BRC322","GSM3818217","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 3","vital status: Alive","follow-up time (month): 154.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC322","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","3","Breast cancer","154.467","Primary breast cancer tumor","Alive"
"GSM3818218","Breast cancer BRC323","GSM3818218","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 65","ajcc stage: 3","vital status: Alive","follow-up time (month): -0.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC323","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","65","3","Breast cancer","-0.2","Primary breast cancer tumor","Alive"
"GSM3818219","Breast cancer BRC325E","GSM3818219","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 51","ajcc stage: 2","vital status: Dead","follow-up time (month): 89.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC325E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","51","2","Breast cancer","89.033","Primary breast cancer tumor","Dead"
"GSM3818220","Breast cancer BRC326","GSM3818220","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 34","ajcc stage: 3","vital status: Alive","follow-up time (month): 113.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC326","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","34","3","Breast cancer","113.033","Primary breast cancer tumor","Alive"
"GSM3818221","Breast cancer BRC327","GSM3818221","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 2","vital status: Alive","follow-up time (month): 25.133","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC327","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","2","Breast cancer","25.133","Primary breast cancer tumor","Alive"
"GSM3818222","Breast cancer BRC328","GSM3818222","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 0","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC328","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","0","Primary breast cancer tumor","Alive"
"GSM3818223","Breast cancer BRC329","GSM3818223","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 1","vital status: Alive","follow-up time (month): 150.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC329","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","1","Breast cancer","150.067","Primary breast cancer tumor","Alive"
"GSM3818224","Breast cancer BRC330","GSM3818224","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 1","vital status: Alive","follow-up time (month): 48.767","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC330","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","1","Breast cancer","48.767","Primary breast cancer tumor","Alive"
"GSM3818225","Breast cancer BRC332","GSM3818225","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Alive","follow-up time (month): 149.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC332","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","149.3","Primary breast cancer tumor","Alive"
"GSM3818226","Breast cancer BRC333","GSM3818226","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 65","ajcc stage: 1","vital status: Dead","follow-up time (month): 56.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC333","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","65","1","Breast cancer","56.9","Primary breast cancer tumor","Dead"
"GSM3818227","Breast cancer BRC334","GSM3818227","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 51","ajcc stage: 1","vital status: Alive","follow-up time (month): 73.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC334","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","51","1","Breast cancer","73.667","Primary breast cancer tumor","Alive"
"GSM3818228","Breast cancer BRC335E","GSM3818228","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 31","ajcc stage: 1","vital status: Alive","follow-up time (month): 143.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC335E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","31","1","Breast cancer","143.333","Primary breast cancer tumor","Alive"
"GSM3818229","Breast cancer BRC336","GSM3818229","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","vital status: Alive","follow-up time (month): 61.733","","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC336","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48",NA,"Breast cancer","61.733","Primary breast cancer tumor","Alive"
"GSM3818230","Breast cancer BRC337","GSM3818230","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 78.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC337","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","78.3","Primary breast cancer tumor","Alive"
"GSM3818231","Breast cancer BRC338","GSM3818231","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 68","ajcc stage: 1","vital status: Alive","follow-up time (month): 74.567","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC338","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","68","1","Breast cancer","74.567","Primary breast cancer tumor","Alive"
"GSM3818232","Breast cancer BRC339","GSM3818232","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 28","ajcc stage: 3","vital status: Alive","follow-up time (month): 76.833","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC339","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","28","3","Breast cancer","76.833","Primary breast cancer tumor","Alive"
"GSM3818233","Breast cancer BRC340","GSM3818233","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 52","ajcc stage: 1","vital status: Alive","follow-up time (month): 69.967","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC340","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","52","1","Breast cancer","69.967","Primary breast cancer tumor","Alive"
"GSM3818234","Breast cancer BRC341","GSM3818234","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 72","ajcc stage: 3","vital status: Alive","follow-up time (month): 79.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC341","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","72","3","Breast cancer","79.667","Primary breast cancer tumor","Alive"
"GSM3818235","Breast cancer BRC343","GSM3818235","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 79.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC343","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","79.067","Primary breast cancer tumor","Alive"
"GSM3818236","Breast cancer BRC344","GSM3818236","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 1","vital status: Alive","follow-up time (month): 74","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC344","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","1","Breast cancer","74","Primary breast cancer tumor","Alive"
"GSM3818237","Breast cancer BRC345","GSM3818237","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 3","vital status: Alive","follow-up time (month): 71.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC345","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","3","Breast cancer","71.9","Primary breast cancer tumor","Alive"
"GSM3818238","Breast cancer BRC346","GSM3818238","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Alive","follow-up time (month): 74.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC346","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","74.3","Primary breast cancer tumor","Alive"
"GSM3818239","Breast cancer BRC347","GSM3818239","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 65","ajcc stage: 1","vital status: Alive","follow-up time (month): 77.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC347","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","65","1","Breast cancer","77.9","Primary breast cancer tumor","Alive"
"GSM3818240","Breast cancer BRC348","GSM3818240","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 39","ajcc stage: 2","vital status: Alive","follow-up time (month): 68.5","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC348","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","39","2","Breast cancer","68.5","Primary breast cancer tumor","Alive"
"GSM3818241","Breast cancer BRC349","GSM3818241","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 49","ajcc stage: 3","vital status: Alive","follow-up time (month): 66.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC349","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","49","3","Breast cancer","66.867","Primary breast cancer tumor","Alive"
"GSM3818242","Breast cancer BRC350","GSM3818242","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 36","ajcc stage: 2","vital status: Alive","follow-up time (month): 71.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC350","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","36","2","Breast cancer","71.6","Primary breast cancer tumor","Alive"
"GSM3818243","Breast cancer BRC351","GSM3818243","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 64","ajcc stage: 1","vital status: Alive","follow-up time (month): 78.433","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC351","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","64","1","Breast cancer","78.433","Primary breast cancer tumor","Alive"
"GSM3818244","Breast cancer BRC352","GSM3818244","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 1","vital status: Alive","follow-up time (month): 89.133","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC352","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","1","Breast cancer","89.133","Primary breast cancer tumor","Alive"
"GSM3818245","Breast cancer BRC355","GSM3818245","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 43","ajcc stage: 2","vital status: Alive","follow-up time (month): 78.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC355","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","43","2","Breast cancer","78.2","Primary breast cancer tumor","Alive"
"GSM3818246","Breast cancer BRC356","GSM3818246","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 2","vital status: Alive","follow-up time (month): 76.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC356","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","2","Breast cancer","76.7","Primary breast cancer tumor","Alive"
"GSM3818247","Breast cancer BRC357","GSM3818247","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 57","ajcc stage: 1","vital status: Alive","follow-up time (month): 79.4","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC357","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","57","1","Breast cancer","79.4","Primary breast cancer tumor","Alive"
"GSM3818248","Breast cancer BRC358","GSM3818248","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 73.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC358","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","73.3","Primary breast cancer tumor","Alive"
"GSM3818249","Breast cancer BRC359","GSM3818249","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 52","ajcc stage: 2","vital status: Alive","follow-up time (month): 73.433","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC359","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","52","2","Breast cancer","73.433","Primary breast cancer tumor","Alive"
"GSM3818250","Breast cancer BRC360","GSM3818250","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 66","ajcc stage: 2","vital status: Alive","follow-up time (month): 72.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC360","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","66","2","Breast cancer","72.7","Primary breast cancer tumor","Alive"
"GSM3818251","Breast cancer BRC361","GSM3818251","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 2","vital status: Alive","follow-up time (month): 78.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC361","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","2","Breast cancer","78.2","Primary breast cancer tumor","Alive"
"GSM3818252","Breast cancer BRC362","GSM3818252","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 52","ajcc stage: 1","vital status: Alive","follow-up time (month): 72.1","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC362","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","52","1","Breast cancer","72.1","Primary breast cancer tumor","Alive"
"GSM3818253","Breast cancer BRC363","GSM3818253","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 1","vital status: Alive","follow-up time (month): 15.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC363","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","1","Breast cancer","15.033","Primary breast cancer tumor","Alive"
"GSM3818254","Breast cancer BRC364","GSM3818254","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 1","vital status: Alive","follow-up time (month): 76.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC364","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","1","Breast cancer","76.8","Primary breast cancer tumor","Alive"
"GSM3818255","Breast cancer BRC365","GSM3818255","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 33","ajcc stage: 3","vital status: Alive","follow-up time (month): 71.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC365","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","33","3","Breast cancer","71.8","Primary breast cancer tumor","Alive"
"GSM3818256","Breast cancer BRC367","GSM3818256","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Alive","follow-up time (month): 71.433","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC367","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","71.433","Primary breast cancer tumor","Alive"
"GSM3818257","Breast cancer BRC368","GSM3818257","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 1","vital status: Alive","follow-up time (month): 76.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC368","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","1","Breast cancer","76.2","Primary breast cancer tumor","Alive"
"GSM3818258","Breast cancer BRC369E","GSM3818258","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 3","vital status: Dead","follow-up time (month): 4.4","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC369E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","3","Breast cancer","4.4","Primary breast cancer tumor","Dead"
"GSM3818259","Breast cancer BRC370","GSM3818259","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 1","vital status: Alive","follow-up time (month): 75.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC370","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","1","Breast cancer","75.533","Primary breast cancer tumor","Alive"
"GSM3818260","Breast cancer BRC371","GSM3818260","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 3","vital status: Alive","follow-up time (month): 85.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC371","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","3","Breast cancer","85.067","Primary breast cancer tumor","Alive"
"GSM3818261","Breast cancer BRC372","GSM3818261","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Alive","follow-up time (month): 78.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC372","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","78.8","Primary breast cancer tumor","Alive"
"GSM3818262","Breast cancer BRC373","GSM3818262","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Alive","follow-up time (month): 76.567","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC373","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","76.567","Primary breast cancer tumor","Alive"
"GSM3818263","Breast cancer BRC374","GSM3818263","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 28","ajcc stage: 2","vital status: Dead","follow-up time (month): 67.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC374","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","28","2","Breast cancer","67.2","Primary breast cancer tumor","Dead"
"GSM3818264","Breast cancer BRC375","GSM3818264","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 34","ajcc stage: 2","vital status: Alive","follow-up time (month): 55.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC375","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","34","2","Breast cancer","55.533","Primary breast cancer tumor","Alive"
"GSM3818265","Breast cancer BRC376","GSM3818265","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 2","vital status: Alive","follow-up time (month): 75.467","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC376","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","2","Breast cancer","75.467","Primary breast cancer tumor","Alive"
"GSM3818266","Breast cancer BRC377","GSM3818266","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 35","ajcc stage: 2","vital status: Alive","follow-up time (month): 72.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC377","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","35","2","Breast cancer","72.067","Primary breast cancer tumor","Alive"
"GSM3818267","Breast cancer BRC378","GSM3818267","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 56","ajcc stage: 2","vital status: Alive","follow-up time (month): 73","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC378","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","56","2","Breast cancer","73","Primary breast cancer tumor","Alive"
"GSM3818268","Breast cancer BRC379","GSM3818268","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 66","ajcc stage: 2","vital status: Alive","follow-up time (month): 86.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC379","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","66","2","Breast cancer","86.3","Primary breast cancer tumor","Alive"
"GSM3818269","Breast cancer BRC382","GSM3818269","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 46.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC382","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","46.6","Primary breast cancer tumor","Alive"
"GSM3818270","Breast cancer BRC383","GSM3818270","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 1","vital status: Alive","follow-up time (month): 91.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC383","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","1","Breast cancer","91.267","Primary breast cancer tumor","Alive"
"GSM3818271","Breast cancer BRC384","GSM3818271","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 3","vital status: Alive","follow-up time (month): 88.167","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC384","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","3","Breast cancer","88.167","Primary breast cancer tumor","Alive"
"GSM3818272","Breast cancer BRC387E","GSM3818272","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 1","vital status: Alive","follow-up time (month): 35.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC387E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","1","Breast cancer","35.667","Primary breast cancer tumor","Alive"
"GSM3818273","Breast cancer BRC398","GSM3818273","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 1","vital status: Alive","follow-up time (month): 68.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC398","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","1","Breast cancer","68.2","Primary breast cancer tumor","Alive"
"GSM3818274","Breast cancer BRC399","GSM3818274","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 36","ajcc stage: 2","vital status: Alive","follow-up time (month): 34.967","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC399","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","36","2","Breast cancer","34.967","Primary breast cancer tumor","Alive"
"GSM3818275","Breast cancer BRC400E","GSM3818275","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Alive","follow-up time (month): 70.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC400E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","70.267","Primary breast cancer tumor","Alive"
"GSM3818276","Breast cancer BRC402","GSM3818276","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 66","ajcc stage: 3","vital status: Alive","follow-up time (month): 89.167","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC402","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","66","3","Breast cancer","89.167","Primary breast cancer tumor","Alive"
"GSM3818277","Breast cancer BRC403","GSM3818277","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 64","ajcc stage: 2","vital status: Alive","follow-up time (month): 86.067","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC403","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","64","2","Breast cancer","86.067","Primary breast cancer tumor","Alive"
"GSM3818278","Breast cancer BRC404","GSM3818278","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 1","vital status: Alive","follow-up time (month): 73.233","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC404","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","1","Breast cancer","73.233","Primary breast cancer tumor","Alive"
"GSM3818279","Breast cancer BRC405","GSM3818279","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 46","ajcc stage: 2","vital status: Alive","follow-up time (month): 88.1","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC405","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","46","2","Breast cancer","88.1","Primary breast cancer tumor","Alive"
"GSM3818280","Breast cancer BRC407","GSM3818280","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Dead","follow-up time (month): 62.267","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC407","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","62.267","Primary breast cancer tumor","Dead"
"GSM3818281","Breast cancer BRC408","GSM3818281","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 1","vital status: Alive","follow-up time (month): 80.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC408","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","1","Breast cancer","80.733","Primary breast cancer tumor","Alive"
"GSM3818282","Breast cancer BRC410","GSM3818282","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 45","ajcc stage: 2","vital status: Alive","follow-up time (month): 74.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC410","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","45","2","Breast cancer","74.867","Primary breast cancer tumor","Alive"
"GSM3818283","Breast cancer BRC411","GSM3818283","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 2","vital status: Alive","follow-up time (month): 75.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC411","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","2","Breast cancer","75.667","Primary breast cancer tumor","Alive"
"GSM3818284","Breast cancer BRC412","GSM3818284","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 63","ajcc stage: 2","vital status: Alive","follow-up time (month): 86.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC412","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","63","2","Breast cancer","86.333","Primary breast cancer tumor","Alive"
"GSM3818285","Breast cancer BRC413","GSM3818285","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 64.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC413","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","64.333","Primary breast cancer tumor","Alive"
"GSM3818286","Breast cancer BRC414","GSM3818286","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 40","ajcc stage: 2","vital status: Alive","follow-up time (month): 85.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC414","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","40","2","Breast cancer","85.9","Primary breast cancer tumor","Alive"
"GSM3818287","Breast cancer BRC415","GSM3818287","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 1","vital status: Alive","follow-up time (month): 60.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC415","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","1","Breast cancer","60.933","Primary breast cancer tumor","Alive"
"GSM3818288","Breast cancer BRC416","GSM3818288","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Alive","follow-up time (month): 75.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC416","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","75.667","Primary breast cancer tumor","Alive"
"GSM3818289","Breast cancer BRC417","GSM3818289","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 2","vital status: Alive","follow-up time (month): 86.633","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC417","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","2","Breast cancer","86.633","Primary breast cancer tumor","Alive"
"GSM3818290","Breast cancer BRC418","GSM3818290","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 33","ajcc stage: 1","vital status: Alive","follow-up time (month): 78.6","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC418","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","33","1","Breast cancer","78.6","Primary breast cancer tumor","Alive"
"GSM3818291","Breast cancer BRC419","GSM3818291","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 63","ajcc stage: 2","vital status: Alive","follow-up time (month): 86.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC419","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","63","2","Breast cancer","86.3","Primary breast cancer tumor","Alive"
"GSM3818292","Breast cancer BRC420","GSM3818292","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 2","vital status: Alive","follow-up time (month): 85.9","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC420","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","2","Breast cancer","85.9","Primary breast cancer tumor","Alive"
"GSM3818293","Breast cancer BRC421","GSM3818293","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 64","ajcc stage: 1","vital status: Alive","follow-up time (month): 82.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC421","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","64","1","Breast cancer","82.2","Primary breast cancer tumor","Alive"
"GSM3818294","Breast cancer BRC422","GSM3818294","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 2","vital status: Alive","follow-up time (month): 35.7","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC422","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","2","Breast cancer","35.7","Primary breast cancer tumor","Alive"
"GSM3818295","Breast cancer BRC423E","GSM3818295","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 2","vital status: Alive","follow-up time (month): 88.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC423E","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","2","Breast cancer","88.8","Primary breast cancer tumor","Alive"
"GSM3818296","Breast cancer BRC424","GSM3818296","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 57","ajcc stage: 2","vital status: Alive","follow-up time (month): 59","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC424","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","57","2","Breast cancer","59","Primary breast cancer tumor","Alive"
"GSM3818297","Breast cancer BRC425","GSM3818297","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 1","vital status: Alive","follow-up time (month): 79.1","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC425","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","1","Breast cancer","79.1","Primary breast cancer tumor","Alive"
"GSM3818298","Breast cancer BRC428","GSM3818298","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 58","ajcc stage: 1","vital status: Alive","follow-up time (month): 122.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC428","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","58","1","Breast cancer","122.933","Primary breast cancer tumor","Alive"
"GSM3818299","Breast cancer BRC430","GSM3818299","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 44","ajcc stage: 2","vital status: Alive","follow-up time (month): 132.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC430","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","44","2","Breast cancer","132.2","Primary breast cancer tumor","Alive"
"GSM3818300","Breast cancer BRC432","GSM3818300","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 34","ajcc stage: 3","vital status: Alive","follow-up time (month): 106.8","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC432","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","34","3","Breast cancer","106.8","Primary breast cancer tumor","Alive"
"GSM3818301","Breast cancer BRC433","GSM3818301","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 41","ajcc stage: 3","vital status: Dead","follow-up time (month): 121.533","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC433","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","41","3","Breast cancer","121.533","Primary breast cancer tumor","Dead"
"GSM3818302","Breast cancer BRC436","GSM3818302","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 48","ajcc stage: 2","vital status: Alive","follow-up time (month): 113.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC436","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","48","2","Breast cancer","113.933","Primary breast cancer tumor","Alive"
"GSM3818303","Breast cancer BRC441","GSM3818303","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 54","ajcc stage: 2","vital status: Alive","follow-up time (month): 133.667","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC441","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","54","2","Breast cancer","133.667","Primary breast cancer tumor","Alive"
"GSM3818304","Breast cancer BRC448","GSM3818304","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 34","ajcc stage: 3","vital status: Alive","follow-up time (month): 63.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC448","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","34","3","Breast cancer","63.733","Primary breast cancer tumor","Alive"
"GSM3818305","Breast cancer BRC449P","GSM3818305","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 50","ajcc stage: 1","vital status: Alive","follow-up time (month): 57.433","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC449P","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","50","1","Breast cancer","57.433","Primary breast cancer tumor","Alive"
"GSM3818306","Breast cancer BRC450P","GSM3818306","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 55","ajcc stage: 2","vital status: Alive","follow-up time (month): 61.1","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC450P","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","55","2","Breast cancer","61.1","Primary breast cancer tumor","Alive"
"GSM3818307","Breast cancer BRC451","GSM3818307","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 38","ajcc stage: 2","vital status: Alive","follow-up time (month): 55.567","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC451","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","38","2","Breast cancer","55.567","Primary breast cancer tumor","Alive"
"GSM3818308","Breast cancer BRC452P","GSM3818308","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 43","ajcc stage: 1","vital status: Alive","follow-up time (month): 60.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC452P","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","43","1","Breast cancer","60.333","Primary breast cancer tumor","Alive"
"GSM3818309","Breast cancer BRC453N","GSM3818309","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 47","ajcc stage: 2","vital status: Alive","follow-up time (month): 57.367","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC453N","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","47","2","Breast cancer","57.367","Primary breast cancer tumor","Alive"
"GSM3818310","Breast cancer BRC454P","GSM3818310","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 37","ajcc stage: 2","vital status: Alive","follow-up time (month): 63.033","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC454P","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","37","2","Breast cancer","63.033","Primary breast cancer tumor","Alive"
"GSM3818311","Breast cancer BRC455","GSM3818311","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 53","ajcc stage: 1","vital status: Alive","follow-up time (month): 61.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC455","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","53","1","Breast cancer","61.333","Primary breast cancer tumor","Alive"
"GSM3818312","Breast cancer BRC456P","GSM3818312","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 70","ajcc stage: 3","vital status: Dead","follow-up time (month): 14.867","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC456P","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","70","3","Breast cancer","14.867","Primary breast cancer tumor","Dead"
"GSM3818313","Breast cancer BRC457P","GSM3818313","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 33","ajcc stage: 3","vital status: Alive","follow-up time (month): 67.2","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC457P","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","33","3","Breast cancer","67.2","Primary breast cancer tumor","Alive"
"GSM3818314","Breast cancer BRC458","GSM3818314","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 51","ajcc stage: 2","vital status: Alive","follow-up time (month): 70.3","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC458","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","51","2","Breast cancer","70.3","Primary breast cancer tumor","Alive"
"GSM3818315","Breast cancer BRC459P","GSM3818315","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 52","ajcc stage: 2","vital status: Alive","follow-up time (month): 31.733","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC459P","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","52","2","Breast cancer","31.733","Primary breast cancer tumor","Alive"
"GSM3818316","Breast cancer BRC460","GSM3818316","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 56","ajcc stage: 2","vital status: Alive","follow-up time (month): 32.933","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC460","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","56","2","Breast cancer","32.933","Primary breast cancer tumor","Alive"
"GSM3818317","Breast cancer BRC461","GSM3818317","Public on Mar 18 2020","May 24 2019","Mar 18 2020","RNA","1","Primary breast cancer","Homo sapiens","disease status: Breast cancer","tissue: Primary breast cancer tumor","age: 42","ajcc stage: 2","vital status: Alive","follow-up time (month): 66.333","total RNA","Total RNA was isolated from tissues with TRIzol (Life Technologies, NY) reagent according to the manufacturer’s protocol. RNA quality and integrity were confirmed by electrophoresis on agarose gel stained with ethidium bromide and examined under ultraviolet light.","biotin","Biotin-labeled cRNA samples for hybridization were prepared according to Illumina’s recommended sample labeling procedure: 500 ng of total RNA was used for cDNA synthesis, followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA using the Illumina® TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX). cRNA concentrations using RiboGreen were measured (Quant-iTTM RiboGreen® RNA assay kit; Invitrogen-Molecular Probes, ON, Canada) by the Victor3 spectrophotometer (PerkinElmer, CT) and cRNA quality was checked on a 1% agarose gel.","9606","Labeled, amplified material (1,500 ng per array) was hybridized to a ver.3 of the Illumina HT-12 expression BeadChip according to the Manufacturer's instructions (Illumina, Inc., San Diego, CA). Array signals were developed by Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the BeadChip manual.","Arrays were scanned with an Illumina BeadArray Reader confocal scanner (BeadStation 500GXDW; Illumina, Inc., San Diego, CA) according to the Manufacturer's instructions.","BRC461","Array data were obtained from Illumina GenomeStudio software. We normalized gene expression data using Quantile normalization and log2 transformation.","GPL6947","Seon-Kyu,,Kim","seonkyu@kribb.re.kr","Personalized Genomic Medicine Research Center","Korea Research Institutue of Bioscience & Biotechnology","125 Gwahak-ro, Yuseong-gu, Daejeon 305-806, Korea","Daejeon","305-806","South Korea","NONE","49576","42","2","Breast cancer","66.333","Primary breast cancer tumor","Alive"
